Medline (NASDAQ:MDLN) Earns Buy Rating from Analysts at Jefferies Financial Group

Investment analysts at Jefferies Financial Group started coverage on shares of Medline (NASDAQ:MDLN) in a research report issued on Monday. The firm set a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group’s target price suggests a potential upside of 23.40% from the company’s previous close.

A number of other brokerages have also weighed in on MDLN. Stifel Nicolaus started coverage on Medline in a research report on Monday. They set a “buy” rating and a $46.00 target price on the stock. Royal Bank Of Canada initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $47.00 price target for the company. Wall Street Zen raised shares of Medline to a “hold” rating in a research note on Saturday. Barclays initiated coverage on shares of Medline in a report on Monday. They set an “overweight” rating and a $50.00 price objective for the company. Finally, Wolfe Research initiated coverage on shares of Medline in a report on Monday. They issued an “outperform” rating and a $47.00 target price on the stock. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average target price of $47.26.

Medline Stock Performance

Shares of NASDAQ:MDLN opened at $40.52 on Monday. Medline has a 52-week low of $34.89 and a 52-week high of $45.50.

Insider Transactions at Medline

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Charles N. Mills purchased 2,579,310 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the transaction, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This represents a -1,870.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.